ciltacabtagene autoleucel
Selected indexed studies
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. (Lancet, 2021) [PMID:34175021]
- Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. (J Clin Oncol, 2023) [PMID:35658469]
- Ciltacabtagene autoleucel for the treatment of multiple myeloma. (Drugs Today (Barc), 2023) [PMID:36811414]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. (2021) pubmed
- Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. (2023) pubmed
- Ciltacabtagene autoleucel for the treatment of multiple myeloma. (2023) pubmed
- Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. (2025) pubmed
- PMID:40138505 (2023) pubmed
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. (2025) pubmed
- Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. (2025) pubmed
- PMID:37934846 (2023) pubmed
- Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. (2025) pubmed
- Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. (2025) pubmed